STOCK TITAN

Nascent Biotech (NBIO) Financials

NBIO OTC
FY2024 annual
Revenue Not reported for FY2024
Net Income -$2.1M YoY not available
EPS (Diluted) Not reported for FY2024
Operating Cash Flow -$1.2M YoY not available
Market Cap $69K as of Nov 12, 2026
Price / Sales n/m no full year of revenue reported yet
Price / Earnings n/m net loss, so no earnings multiple, FY2024
Price / Book n/m negative shareholder equity, so no book multiple, Q1 FY2025

A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Nov 12, 2026; every other figure is from the SEC filings on this page. Not financial advice.

Source SEC Filings Latest period Q1 FY2025, ended Jun 30, 2024 Reported Currency USD FYE March

Newest figures come from the filing for Q1 FY2025, filed Aug 14, 2024. Each column of the statement tables below links to the filing it was taken from.

This page shows Nascent Biotech Inc (NBIO) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 11 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings.

Rhea AI NBIO FY2024

Nascent's 2024 statements show a development-stage business financed externally, with liabilities above assets and operating cash outflows.

In FY2022, a net loss of $470K coexisted with operating cash flow of $413K, showing earnings and cash were then moving differently. By FY2024, operating cash flow was -$1.19M alongside a net loss of $2.09M, making cash funding needs more pronounced than the income statement alone suggests.

FY2024 liabilities of $809K exceeded assets of $552K, leaving negative equity and indicating that obligations were not fully backed by recorded assets. A current ratio of 0.7x shows short-term obligations exceeded short-term assets; because current and total balances are identical, the reported balance sheet is concentrated in current items.

FY2024 financing cash flow of $1.39M exceeded the $1.19M operating cash outflow, indicating external financing supplied cash while operations consumed it. The expense mix also shifted: research and development fell 59.0% from FY2023 while selling, general and administrative expense fell only 0.4%, leaving administration relatively more prominent.

[ NOT FINANCIAL ADVICE ]

Financial Health Signals

Financial health score not available

We do not publish a peer-relative financial health score for Nascent Biotech Inc, because the score only covers companies whose filings and listing give us what it needs to compare them with their peers. The signals and metrics below are current.

Piotroski F-Score Partial
2/5

Nascent Biotech Inc passes 2 of 5 computable financial strength tests (4 of the nine could not be computed from available data). 1 of 3 profitability signals pass, 1 of 2 leverage/liquidity signals pass.

Earnings Quality No Cash Backing
N/A

Nascent Biotech Inc reported a net loss of $2.1M while operations used $1.2M of cash. With neither figure positive, the ratio between the two carries no quality signal.

Interest Coverage At Risk
N/A

Nascent Biotech Inc reported an operating loss of $2.2M against $385K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.

Key Financial Metrics

Export CSV

Earnings & Revenue

Net Income
-$377K

Nascent Biotech Inc reported a net loss of $377K in Q1 2025.

Revenue

Not reported for Q1 2025.

EBITDA

Not reported for Q1 2025.

EPS (Diluted)

Not reported for Q1 2025.

Cash & Balance Sheet

Cash & Debt
$47K
YoY+399.9%
QoQ-87.3%
5Y CAGR+54.5%
10Y CAGR+4.1%

Nascent Biotech Inc held $47K in cash as of Q1 2025; no long-term debt figure is on record for that period.

Shares Outstanding
172M
YoY+15.1%
QoQ0.0%
5Y CAGR+38.7%

Nascent Biotech Inc had 172M shares outstanding in Q1 2025. This represents an increase of 15.1% from the same quarter a year earlier. It is unchanged from the prior quarter.

Free Cash Flow

Not reported for Q1 2025.

Dividends Per Share

Not reported for Q1 2025.

Margins & Returns

None of these metrics is reported for Q1 2025.

Capital Allocation

R&D Spending
$15K
YoY-42.1%

Nascent Biotech Inc invested $15K in research and development in Q1 2025. This represents a decrease of 42.1% from the same quarter a year earlier.

Share Buybacks

Not reported for Q1 2025.

Capital Expenditures

Not reported for Q1 2025.

NBIO Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

NBIO quarterly income statement
MetricQ1'25FilingQ4'24FilingQ3'24FilingQ2'24FilingQ1'24FilingQ4'23FilingQ3'23FilingQ2'23Filing
RevenueN/AN/AN/AN/AN/AN/A$0-100.0%N/A
R&D Expenses$15K-42.1%N/A$47K-15.6%$28K-62.6%$26K-54.5%N/A$56K+36.3%$76K-10.7%
SG&A Expenses$106K+20.9%N/A$102K-23.3%$82K+0.1%$88K-20.0%N/A$133K+88.5%$82K+198.6%
Operating Income-$376KN/A-$364Kn/m-$837Kn/mN/AN/A-$475K-175.3%-$521Kn/m
Interest Expense$2K-99.2%N/A$107-100.0%$125K-54.6%$238K+239.8%N/A$649K+12772.4%$276K+10389.8%
Income TaxN/AN/AN/AN/AN/AN/A$0n/mN/A
Net Income-$377KN/A-$205Kn/m-$829Kn/mN/AN/A-$837K-240.2%-$146Kn/m
EPS (Basic)N/AN/AN/AN/AN/AN/A-$0.01-200.0%N/A
EPS (Diluted)N/AN/AN/AN/AN/AN/A-$0.01-200.0%N/A
Diluted Shares (Avg)N/AN/AN/AN/AN/AN/A120M+6.4%N/A

Not reported in any period shown, so not listed: Cost of Revenue, Gross Profit, EBITDA.

NBIO Balance Sheet

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

NBIO quarterly balance sheet
MetricQ1'25FilingQ4'24FilingQ3'24FilingQ2'24FilingQ1'24FilingQ4'23FilingQ3'23FilingQ2'23Filing
Total Assets$227K+188.1%$552K+116.5%$641K+13.3%$1.0M-13.2%$79K-56.9%$255K+141.9%$566K-24.7%$1.2M+1039.2%
Current Assets$227K+188.1%$552K+116.5%$642K+13.4%$1.0M-13.2%$79K-56.9%$255K+141.9%$566K-24.7%$1.2M+1039.2%
Cash & Equivalents$47K+399.9%$372K+116.1%$624K+11.6%$1.0M-15.1%$9K-93.5%$172K+82.4%$559K+32068.3%$1.2M+1054.4%
Short-Term Investments$0n/m$0n/m$0n/m$0n/m$0n/m$0n/m$0n/m$0n/m
Long-Term Investments$0n/m$0n/m$0n/m$0n/m$0n/m$0n/m$0n/m$0n/m
Total Liabilities$742K-37.9%$809K-47.9%$611K-68.3%$1.0M-56.1%$1.2M-26.3%$1.6M+99.7%$1.9M+60.9%$2.4M+107.6%
Current Liabilities$742K-39.9%$809K-47.9%$611K-68.3%$1.0M-56.1%$1.2M-23.8%$1.6M+99.7%$1.9M+60.9%$2.4M+107.6%
Non-Current Liabilities$0n/m$0n/m$0n/m$0n/m-$40Kn/m$0n/m$0n/m$0n/m
Total Equity-$515Kn/m-$257Kn/m$30Kn/m-$6Kn/m-$1.1Mn/m-$1.3Mn/m-$1.4Mn/m-$1.2Mn/m
Retained Earnings-$24.6Mn/m-$24.3Mn/m-$23.7Mn/m-$23.5Mn/m-$22.2Mn/m-$21.6Mn/m-$21.1Mn/m-$20.3Mn/m

Not reported in any period shown, so not listed: Inventory, Accounts Receivable, Goodwill, Long-Term Debt.

NBIO Cash Flow Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

NBIO quarterly cash flow statement
MetricQ1'25FilingQ4'24FilingQ3'24FilingQ2'24FilingQ1'24FilingQ4'23FilingQ3'23FilingQ2'23Filing
Operating Cash Flow-$325Kn/m-$352Kn/m-$330Kn/m-$342Kn/m-$163Kn/m-$387K-232.1%-$623Kn/m-$434Kn/m
Stock-Based Compensation$0-100.0%N/AN/AN/A$6K-90.7%N/AN/AN/A
Financing Cash FlowN/A$100Kn/m-$50Kn/m$1.3M-9.1%$0-100.0%$0n/m$0n/m$1.5M+1370.0%

Not reported in any period shown, so not listed: Depreciation & Amortization, Capital Expenditures, Free Cash Flow, Investing Cash Flow, Dividends Paid, Share Buybacks.

NBIO Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

NBIO quarterly financial ratios
MetricQ1'25FilingQ4'24FilingQ3'24FilingQ2'24FilingQ1'24FilingQ4'23FilingQ3'23FilingQ2'23Filing
Return on EquityN/AN/A-676.4%N/AN/AN/AN/AN/A
Return on Assets-166.0%N/A-32.0%+116.0pp-79.5%-67.4ppN/AN/A-148.0%-227.4pp-12.1%+188.0pp
Current Ratio0.31+0.2x0.68+0.5x1.05+0.8x0.99+0.5x0.060.0x0.160.0x0.29-0.3x0.50+0.4x
Liabilities-to-EquityN/AN/A20.12N/AN/AN/AN/AN/A
Asset TurnoverN/AN/AN/AN/AN/AN/A0.00-1.3xN/A

Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, Debt-to-Equity, FCF Margin.

Note: Shareholder equity is negative (-$257K), which causes the debt-to-equity, liabilities-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.

Note: The current ratio is below 1.0 (0.68), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.

Similar Companies

Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it. Market cap is stated at each company's latest close.

Company Fiscal year Revenue Net income Net margin Market cap Health score
Nascent Biotech Inc NBIO FY2024 N/A -$2.1M N/A $69K —
Vincerx Pharma Inc VINC FY2024 N/A -$30.1M N/A $79K —
Sigyn Therapeutics Inc SIGY FY2024 N/A N/A N/A $145K —
Ocean Biomedical Inc OCEA FY2024 N/A N/A N/A $23K —
CERo Terapeutics Holding Inc CERO FY2025 N/A N/A N/A $217K —
Regen BioPharma Inc RGBP FY2025 $237K -$1.3M N/A $355K —

Frequently Asked Questions

No, Nascent Biotech Inc (NBIO) reported a net loss of $2.1M in fiscal year 2024.

Nascent Biotech Inc (NBIO) recorded an outflow of $1.2M in operating cash flow during fiscal year 2024, representing cash used by core business activities.

Nascent Biotech Inc (NBIO) had $552K in total assets as of fiscal year 2024, including both current and long-term assets.

Nascent Biotech Inc (NBIO) invested $111K in research and development during fiscal year 2024.

Nascent Biotech Inc (NBIO) had 172M shares outstanding as of fiscal year 2024.

Nascent Biotech Inc (NBIO) had a current ratio of 0.68 as of fiscal year 2024, which is below 1.0, which may suggest potential liquidity concerns.

Nascent Biotech Inc (NBIO) had a return on assets of -378.1% for fiscal year 2024, measuring how efficiently the company uses its assets to generate profit.

Nascent Biotech Inc (NBIO) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (FY2024). The market capitalization is $69K as of Nov 12, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

Nascent Biotech Inc (NBIO) has no price-to-sales ratio at the moment: no full year of revenue reported yet. The market capitalization is $69K as of Nov 12, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

At the end of fiscal year 2024, Nascent Biotech Inc (NBIO) held $372K in cash, cash equivalents and investments, and reported an operating cash outflow of $1.2M over that year. Dividing the one by the other, the reported balance equals about 4 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.

Nascent Biotech Inc (NBIO) has negative shareholder equity of -$257K as of fiscal year 2024, so no debt-to-equity or liabilities-to-equity ratio is reported: dividing debt by equity that is not positive produces a number that cannot be read as leverage. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.

Nascent Biotech Inc (NBIO) has a Piotroski F-Score of 2 out of 5 computable signals; 4 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Nascent Biotech Inc (NBIO) reported a net loss of $2.1M while operations used $1.2M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Nascent Biotech Inc (NBIO) reported an operating loss of $2.2M against $385K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.

Back to top